Please provide your email address to receive an email when new articles are posted on . Olokizumab demonstrated superiority compared with placebo and non-inferiority compared with adalimumab in ...
plaque psoriasis The efficacy, safety, pharmacokinetics, and immunogenicity of adalimumab combined with MTX compared with that adalimumab in patients with chronic plaque psoriasis is evaluated. Adding ...
MONTREAL, Feb. 20, 2019 /CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved HUMIRA® (adalimumab) for the treatment of ...
today announced new clinical trial results showing the subcutaneous (SC) formulation of Orencia^® (abatacept) on a background of methotrexate (MTX) was similar to Humira^® (adalimumab) plus MTX in ...
Amgen is introducing Amjevita (adalimumab-atto), a biosimilar to AbbVie’s Humira. Amjevita was the first biosimilar to Humira approved by the Food and Drug Administration in 2016. "With today's ...
Humira (adalimumab) has potential interactions with several other drugs. For example, taking prednisone with Humira can increase the risk of side effects from both drugs. Humira may also interact with ...
Humira (adalimumab) is a prescription drug used to treat hidradenitis suppurativa (HS). It helps reduce moderate to severe symptoms of this condition. Humira is also available in biosimilar forms.
LONDON, May 25 (Reuters) - Belgian drugmaker UCB is to test its rheumatoid arthritis drug Cimzia in a head-to-head clinical trial against Abbott's Humira, as competition heats up in the market. Humira ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback